Award Number: DAMD17-02-1-0567

TITLE: Effects of Naturally-Occurring Estrogen-Fatty Acid Esters on Mammary Cell Growth and Carcinogenesis in Female Rats

PRINCIPAL INVESTIGATOR: Won Jun Lee

CONTRACTING ORGANIZATION: University of South Carolina Research Foundation Columbia, SC 29208

REPORT DATE: June 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
# Effects of Naturally-Occurring Estrogen-Fatty Acid Esters on Mammary Cell Growth and Carcinogenesis in Female Rats

## Authors
- Won Jun Lee

## Performing Organization
- University of South Carolina Research Foundation
- E-Mail: wonjunlee2002@yahoo.com

## Sponsor
- U.S. Army Medical Research and Materiel Command
- Fort Detrick, Maryland 21702-5012

## Abstract

Research work completed thus far: (1) We have already evaluated the stimulatory effects of estradiol-17β-stearate on the growth of mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. Their effects have been compared with the effects of unesterified estradiol. (2) We have also determined the circulating levels of prolactin, FSH, and LH in all the animals. Right now we are still studying the growth-stimulatory effects of estradiol-17β-stearate and unesterified estradiol in pituitary, thymus, and liver of female rats. (3) We have completed comparing the carcinogenic activity of estradiol-17β-stearate and estradiol mammary vs. uterine cells in female ACI rats. We have also compared and correlated the differential carcinogenic activity of these two classes of estrogens with their differential growth stimulatory effects in various target organs.

The results of our studies shed light on the physiologic and pathophysiologic roles of endogenously-formed estrogen-fatty acid esters in the body. Also, our findings may lead to the development of new strategies to mammary cancer prevention through inhibition of esterase-catalyzed release of bioactive estrogen.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover</td>
<td>1</td>
</tr>
<tr>
<td>SF 298</td>
<td>2</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>3</td>
</tr>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Conclusions</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
Introduction

This is the annual progress report for the Predoctoral Traineeship Award that was originally awarded to Laura H. Mills in early 2002. Around June 2003, the PH.D. Dissertation Committee of Ms. Laura Mills approved her for graduation with a PH.D. Degree. At the request of my supervisor (Professor Bao Ting Zhu), I was named as the replacement P.I. on this grant proposal shortly following Ms. Mills' departure from the project (due to her graduation). After I had carefully read the proposal originally prepared by Dr. Laura Mills, I informed my supervisor that I would be very interested in continuing the studies described in Dr. Mills' proposal. A few months ago, I was approved to serve as the replacement P.I. on this project.

Body

The Specific Aims of the Original Proposal:

I hypothesize that the naturally-occurring estrogen-fatty acid esters may be an especially important group of endogenous estrogens in stimulating cell growth and in inducing tumor formation in the mammary tissues as compared to the uterus. The estrogen-fatty acid ester may serve as a reservoir for the sustained release of 17β-estradiol in mammary glandular cells because they are surrounded by large amounts of adipocytes (which can be a storage site for estrogen esters). In partial support of this hypothesis, my recent study in Dr. Zhu’s lab showed that treatment of female rats with E₂-17β-stearate (0.5 or 5 nmol/day) showed a much stronger growth-stimulatory effect on mammary glandular cells than on the uterine endometrial cells (determined by BrdU incorporation) (39, see Appendix 1). In contrast, E₂ at the same dose showed a stronger growth-stimulatory effect on the uterine cells than on the mammary cells (39). These data revealed, for the first time, that E₂-17β-stearate has a differential, strong hormonal effect in the fat-rich mammary tissues, and this effect was not observed with E₂.

To test this interesting novel hypothesis, I propose the following three specific aims:

Aim 1: I will evaluate the stimulatory effects of E₂-17β-stearate and 4-hydroxyestradiol-17β-stearate, two representative estrogen-fatty acid esters, on the growth of mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. Their effects will be compared with the effects of unesterified E₂ or 4-hydroxyestradiol. The circulating levels of prolactin, FSH, and LH will also be determined in all animals, which will serve as an indicator of estrogen's action on the pituitary. During these animal experiments, I will also collect the pituitary, thymus, and liver, and if time allows, and the growth-stimulatory effects of esterifled vs. unesterified estrogens in these organs will be determined and compared with their effects in the fat-rich mammary tissue.

Aim 2: I will evaluate the carcinogenic activity of E₂-17β-stearate and 4-hydroxyestradiol-17β-stearate on mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. The results will be compared and correlated with the growth stimulatory effects determined under Aim 1.

Aim 3: I will evaluate the activity of estrogen esterase (the enzyme that hydrolyzes estrogen-fatty acid esters to release bioactive estrogens) in the mammary tissue, and its activity will be compared with that found in other organs such as the uterus and liver. These analyses will provide insights into our understanding of the mechanisms underlying a
preferential mitogenic action (and perhaps carcinogenic action) of estrogen-fatty acid esters in the breast over the uterus.

I believe that my proposed studies will provide a preliminary evaluation of the hormonal and carcinogenic actions of a representative fatty acid ester of $E_2$ and 4-hydroxyestradiol in the breast vs. the uterus in female Sprague-Dawley rats. The results of our studies will shed light on the physiologic and pathophysiologic roles of endogenously-formed estrogen-fatty acid esters in the body. Also, if my proposed animal studies demonstrate that various endogenous estrogen-fatty acid esters are stronger and more selective than the unesterified parent hormones in stimulating cell growth and in inducing tumor formation in the fat-rich mammary tissues, this data will form the basis for future epidemiological studies to determine the unique importance of endogenous estrogen-fatty acid esters in human breast cancers. The results of my studies may also lead to the development of new strategies to mammary cancer prevention through inhibition of esterase-catalyzed release of bioactive estrogen.

Research completed thus far:

1. We have already evaluated the stimulatory effects of $E_2$-17$\beta$-stearate on the growth of mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. Their effects have been compared with the effects of unesterified $E_2$.

2. We have also determined the circulating levels of prolactin, FSH, and LH in all the animals. Right now we are still studying the growth-stimulatory effects of $E_2$-17$\beta$-stearate and unesterified $E_2$ in pituitary, thymus, and liver of female rats.

3. We have completed comparing the carcinogenic activity of $E_2$-17$\beta$-stearate and $E_2$ mammary vs. uterine cells in female ACI rats. We have also compared and correlated the differential carcinogenic activity of these two classes of estrogens with their differential growth stimulatory effects in various target organs.

I intend to continue the studies described in Ms. Mills original research proposal. Specifically, I have planned to do the following:

1. I will continue to evaluate the carcinogenic activity of 4-hydroxyestradiol-17$\beta$-stearate on mammary vs. uterine cells in female Sprague-Dawley rats.

2. I will continue to evaluate the activity of estrogen esterase (the enzyme that hydrolyzes estrogen-fatty acid esters to release bioactive estrogens) in the mammary tissue, and its activity will be compared with that found in other organs such as the uterus and liver.

Key Research Accomplishments

1. Our results showed that chronic treatment of ovariectomized female rats with 0.5 or 5 nmol/day of estradiol-17$\beta$-stearate for 10 or 23 days had a stronger stimulatory effect on mammary glandular cell proliferation than treatment with equimolar doses of estradiol-17$\beta$. In the uterus, however, estradiol-17$\beta$ was more active in stimulating the proliferation of uterine endometrial cells than estradiol-17$\beta$-stearate at equimolar doses.
Our results demonstrated, for the first time, that a naturally-occurring estradiol-17β-fatty acid ester has a differential, strong mitogenic effect in the fat-rich mammary tissues, and this effect was not observed with estradiol-17β.

2. We found that none of the control ACI female rats developed mammary tumor and all lived healthily during the 12 month long carcinogenesis experiment. Among the 26 animals receiving an E2 pellet, all the animals developed a large pituitary tumor (average weight = 254 ± 83 mg), but only 8 of them developed mammary tumor(s). A majority of the animals died or had to be terminated early because of severe sickness, due to the presence of the large pituitary tumor. Among the 26 animals implanted with the same molar dose of an E2-fatty acid ester preparation (containing 63% E2-17β-stearate and 37% E2-17β-palmitate), a total of 9 animals developed mammary tumor, and none of the animals died of non-breast cancer-related sickness. Only 3 animals (11.5%; all with mammary tumor) developed a pituitary tumor, with a slightly smaller average size (173 ± 75 mg).

Reportable Outcomes

Listed below are papers and abstracts that have come out of this award. The names of the original P.I. (Laura H. Mills) and the replacement P.I. (Won Jun Lee) are highlighted.


Conclusions

1. Our results demonstrated, for the first time, that a naturally-occurring estradiol-17β-fatty acid ester has a differential, strong mitogenic effect in the fat-rich mammary tissues, and this effect was not observed with estradiol-17β.

2. While $E_2$ was far stronger in stimulating the formation of pituitary tumor (100% incidence) than mammary tumor (30.7% incidence), $E_2$-fatty acid esters had a somewhat stronger activity than $E_2$ in inducing the mammary tumor but only had very weak activity in inducing pituitary tumor. Our data suggest that the endogenous $E_2$-fatty acid esters are pathophysiologically more important than $E_2$ for the selective induction of mammary tumor formation.

References


Appendices

Not included.